Literature DB >> 35123877

Early clinical phenotype of late onset Pompe disease: Lessons learned from newborn screening.

Erin Huggins1, Maggie Holland2, Laura E Case3, Janet Blount1, Andrew P Landstrom4, Harrison N Jones5, Priya S Kishnani6.   

Abstract

PURPOSE: Thoroughly phenotype children with late-onset Pompe disease (LOPD) diagnosed via newborn screening (NBS) to provide guidance for long-term follow up.
METHODS: Twenty infants ages 6-21 months with LOPD diagnosed by NBS underwent systematic clinical evaluation at Duke University including cardiac imaging, biomarker testing, physical therapy evaluation, and speech-language pathology evaluation.
RESULTS: Of the 20 infants, four were homozygous for the "late-onset" IVS1 splice site variant c.-32-13 T > G, fourteen were compound heterozygous, and two did not have any copies of this variant. None of the patients had evidence of cardiomyopathy or cardiac rhythm disturbances. Biomarker testing showed an increase in CK, AST, and ALT in 8 patients (40%) and increase in Glc4 in two patients (10%). All patients demonstrated postural and kinematic concerns. Three patients (17%) scored below the 10%ile on the Alberta Infant Motor Scale (AIMS) and 15 patients (83%) scored above the 10%ile. Speech-language pathology assessments were normal in all patients and mild feeding/swallowing abnormalities were noted in nine patients (45%).
CONCLUSION: Our data show high variability among children with LOPD diagnosed via NBS. Careful physical therapy evaluation is necessary to monitor for subtle musculoskeletal signs that may reflect early muscle involvement. Patients should be monitored closely for symptom progression.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Late-onset Pompe disease; Newborn screening; Pompe disease

Mesh:

Year:  2022        PMID: 35123877     DOI: 10.1016/j.ymgme.2022.01.003

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  3 in total

1.  A Qualitative Study: Mothers' Experiences of Their Child's Late-Onset Pompe Disease Diagnosis Following Newborn Screening.

Authors:  Kaylee Crossen; Lisa Berry; Melanie F Myers; Nancy Leslie; Cecilia Goueli
Journal:  Int J Neonatal Screen       Date:  2022-07-19

2.  Development of a clinically validated in vitro functional assay to assess pathogenicity of novel GAA variants in patients with Pompe disease identified via newborn screening.

Authors:  Shelly Goomber; Erin Huggins; Catherine W Rehder; Jennifer L Cohen; Deeksha S Bali; Priya S Kishnani
Journal:  Front Genet       Date:  2022-09-30       Impact factor: 4.772

Review 3.  The Alberta Infant Motor Scale: A tool for the assessment of motor aspects of neurodevelopment in infancy and early childhood.

Authors:  Małgorzata Eliks; Ewa Gajewska
Journal:  Front Neurol       Date:  2022-09-14       Impact factor: 4.086

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.